This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hecht, J. R. Articles by Freeman, S. M. Search for Related Content PubMed PubMed Citation Articles by Hecht, J. R. Articles by Freeman, S. M.

A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma¹

Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90095 [J. R. H., R. B.]; University of Texas M. D. Anderson Cancer Center, Houston, Texas [J. L. A.]; Medical Clinic of Houston, Houston, TX 77030 [S. L.]; Oxford University Medical School, Mill Valley, CA 94941 [D. H. K.]; Veterans Affairs Palo Alto Health Care System, Palo Alto, California [T. R. R., R. M. S.]; and Onyx Pharmaceuticals, Inc., Richmond, California [S. M. F.]

Purpose: Localized pancreatic carcinoma is rarely resectable and is resistant to conventional therapies. ONYX-015 (dl1520) is an E1B-55kD gene-deleted replication-selective adenovirus that preferentially replicates in and kills malignant cells. Endoscopic ultrasound (EUS) has the potential to conveniently and accurately deliver local therapy to the pancreas. Therefore, we undertook a trial of the feasibility, tolerability, and efficacy of EUS injection of ONYX-015 into unresectable pancreatic carcinomas.

Experimental Design: Twenty-one patients with locally advanced adenocarcinoma of the pancreas or with metastatic disease, but minimal or absent liver metastases, underwent eight sessions of ONYX-015 delivered by EUS injection into the primary pancreatic tumor over 8 weeks. The final four treatments were given in combination with gemcitabine (i.v., 1000 mg/m²). Patients received 2 x 10¹⁰ (n = 3) or 2 x 10¹¹ (n = 18) virus particles/treatment.

Results: After combination therapy, 2 patients had partial regressions of the injected tumor, 2 had minor responses, 6 had stable disease, and 11 had progressive disease or had to go off study because of treatment toxicity. No clinical pancreatitis occurred despite mild, transient elevations in lipase in a minority of patients. Two patients had sepsis before the institution of prophylactic oral antibiotics. Two patients had duodenal perforations from the rigid endoscope tip. No perforations occurred after the protocol was changed to transgastic injections only.

Conclusions: This study indicates that ONYX-015 injection via EUS into pancreatic carcinomas by the transgastic route with prophylactic antibiotics is feasible and generally well tolerated either alone or in combination with gemcitabine. Transgastric EUS-guided injection is a new and practical method of delivering biological agents to pancreatic tumors.

This article has been cited by other articles:

				S. Leitner, K. Sweeney, D. Oberg, D. Davies, E. Miranda, N. R. Lemoine, and G. Hallden Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo Clin. Cancer Res., March 1, 2009; 15(5): 1730 - 1740. [Abstract] [Full Text] [PDF]

				A. L. Angelova, M. Aprahamian, S. P. Grekova, A. Hajri, B. Leuchs, N. A. Giese, C. Dinsart, A. Herrmann, G. Balboni, J. Rommelaere, et al. Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV Clin. Cancer Res., January 15, 2009; 15(2): 511 - 519. [Abstract] [Full Text] [PDF]

				E. C. Verna and V. Dhar Review: Endoscopic ultrasound-guided fine needle injection for cancer therapy: The evolving role of therapeutic endoscopic ultrasound Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 103 - 109. [Abstract] [PDF]

				J. Luo, Q. Xia, R. Zhang, C. Lv, W. Zhang, Y. Wang, Q. Cui, L. Liu, R. Cai, and C. Qian Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene Clin. Cancer Res., April 15, 2008; 14(8): 2450 - 2457. [Abstract] [Full Text] [PDF]

				J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al. Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus Clin. Cancer Res., January 1, 2008; 14(1): 259 - 269. [Abstract] [Full Text] [PDF]

				A. M. Lennon and I. D. Penman Endoscopic ultrasound in cancer staging Br. Med. Bull., December 20, 2007; (2007) ldm033v1. [Abstract] [Full Text] [PDF]

				S. Schepelmann, L. M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, P. Chen, R. Marais, and C. J. Springer Suicide Gene Therapy of Human Colon Carcinoma Xenografts Using an Armed Oncolytic Adenovirus Expressing Carboxypeptidase G2 Cancer Res., May 15, 2007; 67(10): 4949 - 4955. [Abstract] [Full Text] [PDF]

				R. Sinha, G. J. Kim, S. Nie, and D. M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., August 1, 2006; 5(8): 1909 - 1917. [Abstract] [Full Text] [PDF]

				D. Sarkar, Z.-z. Su, N. Vozhilla, E. S. Park, A. Randolph, K. Valerie, and P. B. Fisher Targeted Virus Replication Plus Immunotherapy Eradicates Primary and Distant Pancreatic Tumors in Nude Mice Cancer Res., October 1, 2005; 65(19): 9056 - 9063. [Abstract] [Full Text] [PDF]

				S. Schepelmann, P. Hallenbeck, L. M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, C. Hay, L. K. Hawkins, R. Marais, et al. Systemic Gene-Directed Enzyme Prodrug Therapy of Hepatocellular Carcinoma Using a Targeted Adenovirus Armed with Carboxypeptidase G2 Cancer Res., June 15, 2005; 65(12): 5003 - 5008. [Abstract] [Full Text] [PDF]

				J. Davydova, L. P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment Cancer Res., June 15, 2004; 64(12): 4319 - 4327. [Abstract] [Full Text] [PDF]

				N R Lemoine and I A McNeish Gene transfer: Bax to the future for cancer therapy Gut, April 1, 2004; 53(4): 478 - 479. [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				C. Moon, Y. Oh, and J. A. Roth Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5055 - 5067. [Abstract] [Full Text] [PDF]